​

Galmed Pharmaceuticals (GLMD) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

GLMD Stock Rating

Galmed Pharmaceuticals stock's rating consensus is Buy, based on 16 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (62.50%), 6 Hold (37.50%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 16 0 6 10 Strong Sell Sell Hold Buy Strong Buy

GLMD Price Target Upside V Benchmarks

TypeNameUpside
StockGalmed Pharmaceuticals-
SectorHealthcare Stocks 35.94%
IndustryBiotech Stocks 83.61%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.38$1.38$1.38
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25--1--1
Nov, 24-5---5
Oct, 24-5---5
Sep, 24-5---5
Aug, 2426---8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 24, 2023Maxim GroupBuyupgrade

Financial Forecast

EPS Forecast

$-35 $-28 $-21 $-14 $-7 $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-2.50----
Avg Forecast$-31.56$-15.48$-12.36$-12.12$-12.12
High Forecast$-31.56$-15.48$-12.36$-12.12$-12.12
Low Forecast$-31.56$-15.48$-12.36$-12.12$-12.12
Surprise %-92.08%----

Revenue Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 23Dec 24Dec 25Dec 26Dec 27
Reported-----
Avg Forecast-----
High Forecast-----
Low Forecast-----
Surprise %-----

Net Income Forecast

$-8M $-7M $-6M $-5M $-4M $-3M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-6.91M----
Avg Forecast$-7.28M$-3.57M$-2.85M$-2.80M$-2.80M
High Forecast$-7.28M$-3.57M$-2.85M$-2.80M$-2.80M
Low Forecast$-7.28M$-3.57M$-2.85M$-2.80M$-2.80M
Surprise %-5.11%----

GLMD Forecast FAQ

Is Galmed Pharmaceuticals stock a buy?

Galmed Pharmaceuticals stock has a consensus rating of Buy, based on 16 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 6 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Galmed Pharmaceuticals is a favorable investment for most analysts.

What is Galmed Pharmaceuticals's price target?

Galmed Pharmaceuticals's price target, set by 16 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $1.38.

How does Galmed Pharmaceuticals stock forecast compare to its benchmarks?

Galmed Pharmaceuticals's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (35.94%) and underperforming the biotech stocks industry (83.61%).

What is the breakdown of analyst ratings for Galmed Pharmaceuticals over the past three months?

  • April 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • October 2024: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Galmed Pharmaceuticals’s EPS forecast?

Galmed Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2024 is $-15.48, marking a 519.20% increase from the reported $-2.5 in 2023. Estimates for the following years are $-12.36 in 2025, $-12.12 in 2026, and $-12.12 in 2027.

What is Galmed Pharmaceuticals’s revenue forecast?

Galmed Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2024 is $0, reflecting a 0% decrease from the reported $0 in 2023. The forecast for 2025 is $0, followed by $0 for 2026, and $0 for 2027.

What is Galmed Pharmaceuticals’s net income forecast?

Galmed Pharmaceuticals's net income forecast for the fiscal year ending in December 2024 stands at $-3.573M, representing a -48.31% decrease from the reported $-6.912M in 2023. Projections indicate $-2.853M in 2025, $-2.797M in 2026, and $-2.797M in 2027.